The four main types of blood cancer are leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes (MDS). Each one starts in a different type of blood cell or at a different stage of blood cell development, and they behave in distinct ways. Together, they account for roughly 10% of all new cancer diagnoses in the United States each year.
1. Leukemia
Leukemia is a cancer of the white blood cells. It starts in the bone marrow, where blood cells are made, and causes the body to produce large numbers of abnormal white blood cells that can’t fight infection properly. These faulty cells crowd out healthy blood cells, leading to problems like anemia, frequent infections, and unusual bleeding or bruising.
Doctors classify leukemia along two lines: the type of white blood cell involved and how fast the disease progresses. That gives four major subtypes:
- Acute lymphocytic leukemia (ALL) develops rapidly in immature cells that would normally become lymphocytes (a key part of your immune system). It’s the most common childhood cancer but also occurs in adults.
- Acute myeloid leukemia (AML) also moves fast, but it starts in the cells that would become granulocytes or monocytes, different types of infection-fighting white blood cells.
- Chronic lymphocytic leukemia (CLL) grows slowly in more mature lymphocytes. It’s the most common leukemia in adults and sometimes doesn’t need treatment for years.
- Chronic myeloid leukemia (CML) progresses slowly in myeloid cells and is often caught on routine blood work before symptoms appear.
In acute leukemias, the cancerous cells are immature “blasts” that multiply quickly and can’t perform any immune function. Chronic leukemias involve more mature cells that still do some of their normal work, just not well. This distinction matters because acute forms typically require immediate, intensive treatment, while chronic forms may be managed over a longer timeline. The overall five-year survival rate for leukemia is about 69%, though this varies significantly by subtype and age at diagnosis.
2. Lymphoma
Lymphoma starts in the lymphatic system, the network of vessels, nodes, and organs that filters waste and helps your body fight infection. Unlike leukemia, which primarily fills the bloodstream with abnormal cells, lymphoma typically causes solid tumors in lymph nodes or other lymphatic tissue.
There are two broad categories. Hodgkin lymphoma is identified by the presence of a distinctive abnormal cell called a Reed-Sternberg cell, and it almost always arises from B lymphocytes. Non-Hodgkin lymphoma is everything else. It can develop from B cells, T cells, or natural killer cells, and it includes more than 60 different subtypes ranging from very slow-growing (indolent) to highly aggressive.
Non-Hodgkin lymphoma is far more common. The most frequent symptom is painless swelling of lymph nodes in the neck, armpit, or groin. Other warning signs include drenching night sweats, unexplained weight loss, and persistent fatigue. Hodgkin lymphoma tends to spread in an orderly pattern from one lymph node group to the next, which often makes it easier to stage and treat. Both types generally respond well to modern therapies, and Hodgkin lymphoma in particular has one of the highest cure rates of any cancer.
3. Multiple Myeloma
Multiple myeloma is a cancer of plasma cells, the white blood cells responsible for producing antibodies. Healthy plasma cells make a variety of antibodies to fight different infections. In myeloma, a single plasma cell turns cancerous and multiplies, flooding the bone marrow with copies of itself. All those copies churn out the same nonfunctional antibody protein (called M protein), which builds up in the blood and can damage the kidneys.
Because myeloma cells accumulate inside the bone marrow at multiple sites throughout the skeleton, the disease weakens bones from the inside. This can cause bone pain, fractures, and high calcium levels in the blood as bone breaks down. At the same time, the cancerous plasma cells crowd out normal blood cell production, leading to anemia, low platelet counts, and a weakened immune system. Doctors stage the disease by measuring the amount of M protein in the blood or urine alongside factors like calcium levels, kidney function, and the number of bone lesions visible on imaging.
4. Myelodysplastic Syndromes (MDS)
Myelodysplastic syndromes are a group of cancers in which the bone marrow produces blood cells that don’t mature properly. Instead of developing into healthy red blood cells, white blood cells, and platelets, many of these cells are defective. They either die in the marrow or break down shortly after entering the bloodstream. The result is chronically low blood counts: not enough red cells (causing fatigue and shortness of breath), not enough white cells (raising infection risk), and not enough platelets (causing easy bruising).
MDS is sometimes grouped alongside a related category called myeloproliferative neoplasms (MPNs). Where MDS produces too few functional blood cells, MPNs cause the marrow to overproduce one or more types of blood cells. Some conditions share features of both and are classified as overlap syndromes. MDS is sometimes called a “pre-leukemia” because roughly one-third of cases eventually transform into acute myeloid leukemia.
Common Warning Signs Across All Types
Because all four types disrupt normal blood cell production, they share a surprisingly similar set of early symptoms. Persistent fatigue and weakness are the most common complaints, driven by a shortage of healthy red blood cells. Frequent or severe infections point to compromised white blood cells. Easy bleeding, unusual bruising, recurrent nosebleeds, or tiny red spots on the skin (called petechiae) suggest low platelet counts.
Other signs include unexplained weight loss, fever or chills without an obvious infection, excessive night sweats, swollen lymph nodes, and bone pain or tenderness. None of these symptoms alone means cancer, but several occurring together or lasting more than a few weeks warrants a blood test.
How Blood Cancers Are Diagnosed
The process usually starts with a complete blood count (CBC), a routine test that measures your levels of red cells, white cells, and platelets. If the results show abnormal counts, immature cells in the bloodstream, or an unusual increase in lymphocytes, the next step is often a bone marrow biopsy. A small sample of marrow is drawn from the hip bone and examined under a microscope.
A specialized lab technique called flow cytometry plays a central role in pinpointing the exact type of blood cancer. It works by tagging cells with fluorescent markers, then passing them single file through a laser beam. The way each cell scatters light reveals its size, shape, and surface proteins, allowing pathologists to classify the cancer down to its specific subtype. This matters because treatment varies dramatically depending on whether you’re dealing with, say, CLL versus an aggressive B-cell lymphoma, even though both involve the same type of immune cell. Flow cytometry is also used after treatment to check whether the cancer has returned.
Treatment Approaches
Treatment for blood cancers has changed dramatically in the past two decades. Traditional chemotherapy remains a foundation for many cases, but targeted therapies, which attack specific vulnerabilities in cancer cells rather than killing all fast-dividing cells, have become standard for several subtypes.
Stem cell transplants are used when doctors need to essentially replace a patient’s bone marrow. After high-dose chemotherapy destroys both cancer cells and normal marrow, donated or previously collected stem cells are infused to rebuild the blood-forming system. This approach carries significant risks but can be curative for certain leukemias and lymphomas.
One of the most notable advances is CAR T-cell therapy. Doctors collect a patient’s own immune cells, genetically reprogram them in a lab to recognize proteins on the surface of cancer cells, then grow hundreds of millions of these enhanced cells and infuse them back into the patient. There are now several FDA-approved CAR T-cell products for conditions including B-cell acute lymphoblastic leukemia, several types of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma. The therapy can cause intense short-term side effects as the reprogrammed cells flood the body with inflammatory signals, but for patients who’ve run out of other options, it has produced durable remissions that weren’t possible a decade ago.